International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
-
Int. J. Gynecol. Cancer · Feb 2012
Meta AnalysisTumor necrosis factor α -308 G>A polymorphisms and cervical cancer risk: a meta-analysis.
Tumor necrosis factor α (TNF-α), secreted mainly by activated macrophages, is recently involved in fighting against tumorigenesis. Tumor necrosis factor α -308 G>A, the common polymorphism in the promoter of TNF-α, has been implicated to alter the risk of cervical cancer, yet the results of relative studies are inconclusive or controversial. To derive a more precise estimation of the relationship, we performed a meta-analysis based on 8 studies. ⋯ The natural genetic polymorphism in TNF-α -308 G>A is a risk factor for developing cervical cancer, especially for Asians and whites.
-
Int. J. Gynecol. Cancer · Feb 2012
Intraperitoneal chemotherapy for recurrent epithelial ovarian cancer is feasible with high completion rates, low complications, and acceptable patient outcomes.
Three large randomized clinical trials have shown a survival benefit for patients treated with intraperitoneal (IP) compared with intravenous chemotherapy for advanced stage epithelial ovarian cancer (EOC). However, the use of IP chemotherapy in recurrent EOC is controversial. The purpose of this study was to determine outcomes, completion rates, and frequency of complications in patients with platinum-sensitive recurrent EOC treated with IP chemotherapy. ⋯ Intraperitoneal chemotherapy is a feasible option for patients with recurrent EOC, with high completion rates, low frequency of complications, and acceptable PFS and OS.
-
Int. J. Gynecol. Cancer · Jan 2012
Impact of chemotherapy-induced nausea and vomiting on quality of life in indonesian patients with gynecologic cancer.
Quality of life (QoL) has become a major outcome in the treatment of patients with cancer. This study is aimed at examining the impact of chemotherapy-induced nausea and vomiting on QoL of patients with gynecologic cancer in Indonesia. ⋯ Patients reported a negative impact on the QoL of delayed emesis after chemotherapy. Poor prophylaxis of patients' nausea and vomiting after chemotherapy interferes with patients' QoL. Medical and behavioral interventions may help to alleviate the negative consequences of chemotherapeutic treatment in patients with gynecologic cancers treated with suboptimal antiemetics.
-
Int. J. Gynecol. Cancer · Dec 2011
ReviewRoutine hysterectomy in the surgical management of ovarian cancer: a retrospective case series, physician opinion survey, and review of the literature.
Current international guidelines recommend routine hysterectomy in the initial surgical management of epithelial ovarian cancer. However, there seems to be limited evidence to support these recommendations. We examined the data for a series of women undergoing hysterectomy as part of surgical management of ovarian cancer. ⋯ The incidence of synchronous primary endometrial cancers was 5%, and preoperative ultrasound had a sensitivity of 82% for predicting endometrial pathology. We also surveyed the members of the Australian Society of Gynaecological Oncologists (ASGO) regarding the role of hysterectomy in the management of ovarian cancer. Most of the respondents indicated that they believe hysterectomy should be routinely performed in the management of ovarian cancer but acknowledge that there is a lack of evidence to support the practice.
-
Int. J. Gynecol. Cancer · Oct 2011
Clinical TrialExtended-field irradiation and intracavitary brachytherapy combined with cisplatin and amifostine for cervical cancer with positive para-aortic or high common iliac lymph nodes: results of arm II of Radiation Therapy Oncology Group (RTOG) 0116.
Radiation Therapy Oncology Group (RTOG) 0116 was designed to test the ability of amifostine (Ethyol; MedImmune LLC, Gaithersburg, MD), a cytoprotective agent, to reduce the acute toxicity of combined therapy with extended-field irradiation, brachytherapy, and cisplatin chemotherapy in patients with cervical cancer with para-aortic or high common iliac disease. This report presents the results of part 2. ⋯ Amifostine, as delivered in this study, did not reduce acute toxicity in this patient population.